Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Gynecol Oncol. 2017 Oct 14;147(3):695–704. doi: 10.1016/j.ygyno.2017.10.003

Figure 3. PARPi resistance is mediated through a variety of targetable pathways.

Figure 3

The FDA has approved three PARPi for ovarian cancer and as PARPi are commonly prescribed there will be an increase in acquired resistance. Currently, several targetable pathways (HR restoration, PI3K/AKT, miRNA) have been attributed to resistance.